Showing results (201-210 of 250) with videos related to

Sort By:
Pageof 25
The Oncologist|February 13, 2001
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexaroteneM H Cohen, S Hirschfeld, S Flamm Honig, et al.
Cancer Treatment Reports|June 1, 1985
Treatment of non-small cell bronchogenic carcinoma with vinblastine and mitomycin: a Southwest Oncology Group StudyJ K Weick, J M Rainey, R B Livingston, et al.
Journal of Studies on Alcohol|July 1, 1985
Reactivity to alcohol-related cues: physiological and subjective responses in alcoholics and nonproblem drinkersR F Kaplan, N L Cooney, L H Baker, et al.
Investigational New Drugs|August 1, 1991
Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinomaJ A Ajani, R Pazdur, R J Winn, et al.
Journal of Neurosurgery|June 1, 1985
Epidemiological findings in a brain-tumor cluster in western MissouriR A Morantz, J S Neuberger, L H Baker, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1994
Phase II trial of recombinant human macrophage colony-stimulating factor in metastatic soft tissue sarcomaF A Momin, M Zalupski, L K Heilbrun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancerP M Hoff, N Janjan, E D Saad, et al.
Investigational New Drugs|July 30, 1999
Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinomaR Pazdur, D C Medgyesy, R J Winn, et al.
Cancer|April 7, 1998
A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcomaK Antman, J Crowley, S P Balcerzak, et al.
Cancer|March 1, 1984
Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group studyM K Samson, S E Rivkin, S E Jones, et al.
Pageof 25